News
-
10 Nov, 2021
Spago Nanomedical selects Cmed as its CRO for the first clinical trial with Tumorad®
-
10 Nov, 2021
Spago Nanomedical anlitar Cmed som CRO för den första kliniska studien med Tumorad®
-
21 Oct, 2021
Nomination committee appointed for the 2022 Annual General Meeting in Spago Nanomedical
-
21 Oct, 2021
Valberedning utsedd inför Spago Nanomedicals årsstämma 2022
-
24 Aug, 2021
Spago Nanomedical halvårsrapport januari-juni 2021
-
24 Aug, 2021
Spago Nanomedical interim report January-June 2021
-
3 Aug, 2021
Spago Nanomedical utser Paul Hargreaves till Chief Development Officer
-
3 Aug, 2021
Spago Nanomedical appoints Paul Hargreaves as Chief Development Officer
-
5 May, 2021
Bulletin from the 2021 Annual General Meeting of Spago Nanomedical AB (publ)
-
5 May, 2021
Kommuniké från årsstämma 2021 i Spago Nanomedical AB (publ)